Genetic Testing Market Size & Share to Boom at Double-Digit CAGR During Forecast Year 2020-2030
Market Overview
Genetic tests are medical instruments that come in the form of kits or panels and are used to diagnose genetic illnesses in people. Furthermore, blood samples from patients are collected throughout the exam. These samples are then tested utilizing test kits on laboratory equipment. Measurement of the results of genetic alterations, such as RNA analysis as an output of gene expression, or biochemical analysis to quantify particular protein production, are examples of genetic testing. Numerous sorts of tests are utilized to diagnose genetic abnormalities. Predictive testing, carrier testing, prenatal and neonatal testing, diagnostic testing, pharmacogenomic testing, nutrigenomics, and other genetic tests are available to detect diseases. Newborn testing, for example, can detect genetic diseases early in life, allowing treatment to begin as soon as feasible. In addition, these tests are utilized to diagnose medical disorders such as cancer, hereditary disorders, and cardiovascular disease.
Genetic testing market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bio-Rad Laboratories Inc.
Myriad Genetics, Inc. (Myriad RBM, Inc.)
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche AG
Eurofins Scientific
Illumina Inc.
Thermo Fisher Scientific
Danaher Corporation (Cepheid Inc)
RainDance Technologies Inc.
Growth Factor
Genetic testing for Cancer cure
According to the World Health Organization, cancer led to the deaths of 9.6 million people globally in 2018. These figures are concerning since the illness is at an all-time high, impacting the whole planet and bordering on epidemic proportions. Breast cancer, ovarian cancer, bowel cancer, womb cancer, and prostate cancer can all be diagnosed quickly thanks to genetic testing. A family history of cancer is required for genetic testing and assistance in the prevention of this devastating illness. This application sector was one of the most popular in the genetic testing market, and it is predicted to continue to develop gradually in future.
Segmentation
By Types of Testing
Newborn Screening
Diagnostic Testing
Carrier Testing
Prenatal Testing
Forensic Testing
Predictive and Presymptomatic Testing
Others
By Methods
Molecular Genetic Testing
Chromosomal Genetic Testing
Biochemical Genetic Testing
Others
By Testing Sample
Blood
Saliva
Hair
Tumors
Others
By Industry
Laboratories
Blood Banks
Nursing Homes
Hospitals
Others
Genetic Testing Market Dynamics
Genetic Testing Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
The FDA extended the approval of a cancer blood test called "liquid biopsy" in November 2020, which identifies genetic changes in tumor DNA in the blood and can assist match patients to prospective therapies.
In August 2020, Guardant360 CDx of Guardant Health and FoundationOne Liquid CDx of Foundation Medicine were authorized by the FDA for use as a companion diagnostic test and for general tumor profiling.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Genetic testing market growth?
Which segment accounted for the largest Genetic testing market share?
Who are the key players in the Genetic testing market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Genetic tests are medical instruments that come in the form of kits or panels and are used to diagnose genetic illnesses in people. Furthermore, blood samples from patients are collected throughout the exam. These samples are then tested utilizing test kits on laboratory equipment. Measurement of the results of genetic alterations, such as RNA analysis as an output of gene expression, or biochemical analysis to quantify particular protein production, are examples of genetic testing. Numerous sorts of tests are utilized to diagnose genetic abnormalities. Predictive testing, carrier testing, prenatal and neonatal testing, diagnostic testing, pharmacogenomic testing, nutrigenomics, and other genetic tests are available to detect diseases. Newborn testing, for example, can detect genetic diseases early in life, allowing treatment to begin as soon as feasible. In addition, these tests are utilized to diagnose medical disorders such as cancer, hereditary disorders, and cardiovascular disease.
Genetic testing market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bio-Rad Laboratories Inc.
Myriad Genetics, Inc. (Myriad RBM, Inc.)
Danaher Corporation (Cepheid)
F. Hoffmann-La Roche AG
Eurofins Scientific
Illumina Inc.
Thermo Fisher Scientific
Danaher Corporation (Cepheid Inc)
RainDance Technologies Inc.
Growth Factor
Genetic testing for Cancer cure
According to the World Health Organization, cancer led to the deaths of 9.6 million people globally in 2018. These figures are concerning since the illness is at an all-time high, impacting the whole planet and bordering on epidemic proportions. Breast cancer, ovarian cancer, bowel cancer, womb cancer, and prostate cancer can all be diagnosed quickly thanks to genetic testing. A family history of cancer is required for genetic testing and assistance in the prevention of this devastating illness. This application sector was one of the most popular in the genetic testing market, and it is predicted to continue to develop gradually in future.
Segmentation
By Types of Testing
Newborn Screening
Diagnostic Testing
Carrier Testing
Prenatal Testing
Forensic Testing
Predictive and Presymptomatic Testing
Others
By Methods
Molecular Genetic Testing
Chromosomal Genetic Testing
Biochemical Genetic Testing
Others
By Testing Sample
Blood
Saliva
Hair
Tumors
Others
By Industry
Laboratories
Blood Banks
Nursing Homes
Hospitals
Others
Genetic Testing Market Dynamics
Genetic Testing Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
The FDA extended the approval of a cancer blood test called "liquid biopsy" in November 2020, which identifies genetic changes in tumor DNA in the blood and can assist match patients to prospective therapies.
In August 2020, Guardant360 CDx of Guardant Health and FoundationOne Liquid CDx of Foundation Medicine were authorized by the FDA for use as a companion diagnostic test and for general tumor profiling.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Genetic testing market growth?
Which segment accounted for the largest Genetic testing market share?
Who are the key players in the Genetic testing market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. EXECUTIVE SUMMARY
2. GLOBAL GENETIC TESTING MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL GENETIC TESTING MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL GENETIC TESTING MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL GENETIC TESTING MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa, UAE and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico and Argentina, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Types of Testing: Market Share (2020-2030F)
12.2.1. Newborn Screening, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Diagnostic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Carrier testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Prenatal testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Forensic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Predictive and presymtomatic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.7. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Methods: Market Share (2020-2030F)
12.3.1. Molecular Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Chromosomal Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Biochemical Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Testing Sample: Market Share (2020-2030F)
12.4.1. Blood, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Saliva, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Hair, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Tumors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By Industry: Market Share (2020-2030F)
12.5.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Nursing homes, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.3. Blood Banks, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.4. Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.6. Company Profile
12.7. Abbott Laboratories
12.7.1. Company Overview
12.7.2. Company Total Revenue (Financials)
12.7.3. Market Potential
12.7.4. Global Presence
12.7.5. Key Performance Indicators
12.7.6. SWOT Analysis
12.7.7. Product Launch
12.8. Bio-Rad Laboratories Inc.
12.9. Myriad Genetics, Inc. (Myriad RBM, Inc.)
12.10. Danaher Corporation (Cepheid)
12.11. F. Hoffmann-La Roche AG
12.12. Eurofins Scientific
12.13. Illumina Inc.
12.14. Thermo Fisher Scientific
12.15. Danaher Corporation (Cepheid Inc)
12.16. RainDance Technologies Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL GENETIC TESTING MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL GENETIC TESTING MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL GENETIC TESTING MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL GENETIC TESTING MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa, UAE and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico and Argentina, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Types of Testing: Market Share (2020-2030F)
12.2.1. Newborn Screening, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Diagnostic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Carrier testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Prenatal testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Forensic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Predictive and presymtomatic testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.7. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Methods: Market Share (2020-2030F)
12.3.1. Molecular Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Chromosomal Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Biochemical Genetic Testing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Testing Sample: Market Share (2020-2030F)
12.4.1. Blood, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Saliva, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Hair, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Tumors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By Industry: Market Share (2020-2030F)
12.5.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Nursing homes, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.3. Blood Banks, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.4. Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.6. Company Profile
12.7. Abbott Laboratories
12.7.1. Company Overview
12.7.2. Company Total Revenue (Financials)
12.7.3. Market Potential
12.7.4. Global Presence
12.7.5. Key Performance Indicators
12.7.6. SWOT Analysis
12.7.7. Product Launch
12.8. Bio-Rad Laboratories Inc.
12.9. Myriad Genetics, Inc. (Myriad RBM, Inc.)
12.10. Danaher Corporation (Cepheid)
12.11. F. Hoffmann-La Roche AG
12.12. Eurofins Scientific
12.13. Illumina Inc.
12.14. Thermo Fisher Scientific
12.15. Danaher Corporation (Cepheid Inc)
12.16. RainDance Technologies Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
